Why Leen Kawas Believes Visibility Matters for Women Founders
On a video call between Seattle, Los Angeles and Amman, a young scientist-turned-founder walks through her first pitch deck. The slides describe a platform for neurodegenerative disease. The science is strong. The business model is still rough. On the other end of the call sits Leen Kawas, who has already navigated many of the steps this founder hopes to take: discovery, clinical translation, venture financing, the roadshow, the bell.
Kawas listens, asks about controls and endpoints, then shifts the conversation. She wants to know when the founder last saw someone who looked like her leading a biotech on CNBC or sitting at the head of a board table. The question sounds personal, yet it points to a structural issue she has spent the last several years trying to change.
A rare journey into the public markets
Leen Kawas arrived in the United States from Jordan in 2008 to pursue a PhD in molecular pharmacology at Washington State University, after training as a pharmacist at the University of Jordan. During her graduate work she became deeply involved in drug development for neurodegenerative disease. That research became the seed of Athira Pharma, which she co-founded in 2011. She stepped into the CEO role in 2014 and led the company as it advanced multiple later-stage clinical programs.
In September 2020 Athira went public on the Nasdaq, raising about 204 million dollars in its IPO and more than 400 million dollars across public and private financings. At the time, she was one of roughly twenty two women founders and CEOs who had taken a company public in the United States, and the first woman in more than two decades to bring a company to an IPO from Washington state.
That experience left her with a clear impression. The pipeline of women leading deep tech and biotech companies is far larger than the tiny fraction who appear at the helm of IPO-bound firms. Visibility gaps hide that reality.
The numbers behind the visibility problem
Kawas often frames her own IPO as an outlier in a wider data set. Even as of 2025, companies founded solely by women receive a small single-digit share of US venture capital, with estimates hovering around 1 to 3 percent of total dollars depending on the year and methodology. As explored in this piece on Billion Success, female-founded firms have begun to represent a larger portion of IPOs, roughly one in ten by recent counts, yet they remain a clear minority.
Reports that track exits show that women-led companies often generate strong revenue per dollar invested and meaningful contributions to venture-backed exits, despite chronic underfunding. In that context, Kawas sees each visible success story as doing two jobs at once. It validates the individual company. It also disrupts the mental model that investors, journalists and younger founders carry about who leads high-growth science businesses.
On her personal site she describes herself as a strong supporter of entrepreneurs in science, with a particular desire to help women in the industry and to level the playing field for them. For her, visibility is the lever that connects these statistics to changed behavior.
Creating compounding effects for the next generation
Kawas is acutely aware that a single IPO cannot fix systemic imbalance. She views visibility as a starting condition for compounding change rather than a solution by itself. Each time a woman founder takes a company public, raises a large round or leads a significant partnership, three effects begin to accumulate.
First, networks shift. Founders who have crossed those thresholds tend to mentor others, join boards and sit on investment committees. Kawas uses her own platform at Propel Bio Partners to bring more diverse founders into investor conversations and to advocate for inclusive hiring and board-building in portfolio companies.
Second, institutional memory evolves. When firms have seen women-led companies perform, internal case studies begin to feature those examples. That changes how partners debate risk.
Third, younger scientists adjust their ambitions. Kawas often meets early-career researchers who grew up hearing about male biotech icons. When they encounter a woman who has moved from the bench to the bell, the path feels more reachable.
Why she keeps pushing the spotlight outward
Today, split between operating, investing and board service, Leen Kawas spends much of her time in rooms where capital and scientific ideas meet. She has already felt what it is like to be treated as an exception. Her current work aims to ensure that younger founders do not carry that same label when they step on stage.
Visibility, in her view, is not about personal brand. It is a resource that can be directed. She can choose which founders appear on panels, which stories she highlights in essays, which teams she introduces to investors. By doing that with intent, she tries to move women-led science companies from the margins of the data to the center of the narrative.
The biotech sector will still measure success in clinical milestones, regulatory approvals and shareholder returns. Kawas does not dispute that. She simply argues that when more women are visible at the helm of companies that achieve those milestones, the entire system gains a broader field of vision.
Learn more about Leen Kawas in this rapid fire-style interview on Principal Post.